[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619811":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":25,"locations":30,"responsibleParty":50,"collaborators":25,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":25,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":25,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":25,"overallStatus":33,"whyStopped":25,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control group","ACTIVE_COMPARATOR","Group 1 (Placebo Group): Participants in this arm were administered an inert placebo capsule twice per day, in combination with mesalamine at a total daily dose of 3 g, given as 1 g three times daily",[13],"Drug: Mesalamine",{"label":15,"type":10,"description":16,"interventionNames":17},"Pentoxifylline group","Group 2 (PTX Group): Individuals assigned to this group received PTX at a dose of 400 mg twice daily, together with mesalamine 1 g taken three times daily.",[13,18],"Drug: Pentoxifylline",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Mesalamine","Mesalamine is the standard first line treatment of ulcerative colitis",[9,15],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Pentoxifylline","Pentoxifylline (PTX), a methylxanthine derivative and non-selective phosphodiesterase inhibitor, has been extensively studied for its anti-inflammatory and immunomodulatory actions. It inhibits TNF-α production at the transcriptional level and downregulates several inflammatory cytokines, including IL-1β, IL-6, and interferon-γ",[15],[31],{"facility":32,"status":33,"city":34,"state":25,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Fayoum University","RECRUITING","Al Fayyum","54687","Egypt","EG",{"type":39,"coordinates":40},"Point",[41,42],30.8418,29.30995,{"lat":42,"lon":41},[45],{"name":46,"role":47,"phone":48,"phoneExt":25,"email":49},"Ehab Hassan, PhD","CONTACT","01067831661","Ehassan@horus.edu.eg",{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Ihab Elsayed Hassan","Lecturer","100619811","phase-2-pentoxifylline-in-patients-with-ulcerative-colitis-100619811",false,"NCT07349472","Pentoxifylline in Patients With Ulcerative Colitis","Clinical Study Evaluating Safety and Efficacy of Pentoxifylline in Patients With Ulcerative Colitis","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Both male and female will be included\n* Negative pregnancy test and effective contraception.\n* Mild and moderate UC patients\n\nExclusion Criteria:\n\n* Breast feeding\n* Significant liver and kidney function abnormalities\n* Diabetic patients\n* Colorectal cancer patients\n* Patients with severe UC\n* Patients taking rectal or systemic steroids\n* Patients taking immunosuppressives or biological therapies\n* Addiction to alcohol and \u002F or drugs\n* Known allergy to the studied medications","ALL","18 Years","70 Years",{"count":65,"type":66},60,"ESTIMATED","INTERVENTIONAL",[69],"PHASE2","Ulcerative colitis (UC) is a persistent, idiopathic form of inflammatory bowel disease (IBD) marked by uninterrupted inflammation of the colon's mucosal lining, usually starting at the rectum and progressing proximally in a continuous manner. It manifests clinically with recurrent episodes of abdominal pain, bloody diarrhea, urgency, tenesmus, and weight loss. The precise cause of UC is still unknown; however, it is thought to arise from a multifactorial interaction involving genetic susceptibility, immune system dysregulation, disturbances in gut microbiota composition, and various environmental factors.",[72],"Inflammatory Bowel Diseases","2026-04-11",{"date":75,"type":76},"2026-04-15","ACTUAL",{"date":78,"type":76},"2026-01-20",{"date":80,"type":66},"2027-02-20",{"name":52,"class":6},1]